tetano
Editor, Senior Moderator
Sci Adv
. 2024 May 24;10(21):eadl5762.
doi: 10.1126/sciadv.adl5762. Epub 2024 May 24. Longitudinal plasma proteomic analysis of 1117 hospitalized patients with COVID-19 identifies features associated with severity and outcomes
Arthur Viode[SUP] 1 2 [/SUP], Kinga K Smolen[SUP] 2 3 [/SUP], Patrick van Zalm[SUP] 1 2 4 [/SUP], David Stevenson[SUP] 1 [/SUP], Meenakshi Jha[SUP] 1 [/SUP], Kenneth Parker[SUP] 1 [/SUP]; IMPACC Network‡; Ofer Levy[SUP] 2 3 5 [/SUP], Judith A Steen[SUP] 2 6 7 [/SUP], Hanno Steen[SUP] 1 2 3 7 [/SUP]
Affiliations
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is characterized by highly heterogeneous manifestations ranging from asymptomatic cases to death for still incompletely understood reasons. As part of the IMmunoPhenotyping Assessment in a COVID-19 Cohort study, we mapped the plasma proteomes of 1117 hospitalized patients with COVID-19 from 15 hospitals across the United States. Up to six samples were collected within ~28 days of hospitalization resulting in one of the largest COVID-19 plasma proteomics cohorts with 2934 samples. Using perchloric acid to deplete the most abundant plasma proteins allowed for detecting 2910 proteins. Our findings show that increased levels of neutrophil extracellular trap and heart damage markers are associated with fatal outcomes. Our analysis also identified prognostic biomarkers for worsening severity and death. Our comprehensive longitudinal plasma proteomics study, involving 1117 participants and 2934 samples, allowed for testing the generalizability of the findings of many previous COVID-19 plasma proteomics studies using much smaller cohorts.
. 2024 May 24;10(21):eadl5762.
doi: 10.1126/sciadv.adl5762. Epub 2024 May 24. Longitudinal plasma proteomic analysis of 1117 hospitalized patients with COVID-19 identifies features associated with severity and outcomes
Arthur Viode[SUP] 1 2 [/SUP], Kinga K Smolen[SUP] 2 3 [/SUP], Patrick van Zalm[SUP] 1 2 4 [/SUP], David Stevenson[SUP] 1 [/SUP], Meenakshi Jha[SUP] 1 [/SUP], Kenneth Parker[SUP] 1 [/SUP]; IMPACC Network‡; Ofer Levy[SUP] 2 3 5 [/SUP], Judith A Steen[SUP] 2 6 7 [/SUP], Hanno Steen[SUP] 1 2 3 7 [/SUP]
Affiliations
- PMID: 38787940
- PMCID: PMC11122669
- DOI: 10.1126/sciadv.adl5762
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is characterized by highly heterogeneous manifestations ranging from asymptomatic cases to death for still incompletely understood reasons. As part of the IMmunoPhenotyping Assessment in a COVID-19 Cohort study, we mapped the plasma proteomes of 1117 hospitalized patients with COVID-19 from 15 hospitals across the United States. Up to six samples were collected within ~28 days of hospitalization resulting in one of the largest COVID-19 plasma proteomics cohorts with 2934 samples. Using perchloric acid to deplete the most abundant plasma proteins allowed for detecting 2910 proteins. Our findings show that increased levels of neutrophil extracellular trap and heart damage markers are associated with fatal outcomes. Our analysis also identified prognostic biomarkers for worsening severity and death. Our comprehensive longitudinal plasma proteomics study, involving 1117 participants and 2934 samples, allowed for testing the generalizability of the findings of many previous COVID-19 plasma proteomics studies using much smaller cohorts.